Following Zogenix’s (NASDAQ: ZGNX) first-quarter results, Aegis Capital has reiterated its ‘Buy’ rating and price target of $28 on shares of the company’s stock. Zogenix reported total revenue for the first quarter of $2.7 million, consisting entirely of contract manufacturing revenue. Additionally, Zogenix recently said it has completed enrollment in Study 1, the first phase 3 clinical trial evaluating ZX008 as an adjunctive treatment for seizures in children and young adults with Dravet syndrome. Top-line data from Study 1 is anticipated in the third quarter of 2017. The company is currently enrolling for 1504, the second pivotal phase 3 trial in the U.S., with data expected by the first quarter of 2018.
For more information, visit www.zogenix.com
Zogenix, Inc. is a pharmaceutical company committed to developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer